Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Achaogen Gets Federal Funding for Biowarfare Agent Therapeutic Development

by Global Biodefense Staff
October 9, 2017
Health Security Notable Contracts

The U.S. federal government is backing an antibiotic that not only holds potential as a treatment for infections from certain types of drug-resistant bacteria but also may be able to combat infections caused by bacteria used in biowarfare.

Early testing suggests that Achaogen, Inc.’s C-scape could provide protection against the biowarfare agents Yersinia pestis, which causes plague, and Francisella tularensis, which causes tularemia. The contract will support the study of the drug’s potential as a treatment for exposure to these agents.

The drug would be administered orally and is being developed as a two-component drug, combining an antibiotic (a beta-lactam) with a compound that inhibits certain enzymes, called Extended Spectrum Beta-Lactamases, or ESBLs. That combination should allow the antibiotic to be effective against bacterial strains that otherwise would be resistant to the drug alone.

“Combating antibiotic-resistant infections is fundamental to U.S. biodefense,” explained Biomedical Advanced Research and Development Authority (BARDA) Director Rick Bright, Ph.D. “The long hospitalizations that may be likely after a bioterrorism attack leave Americans open to secondary drug-resistant infections, which means to be prepared for bioterrorism, we need to have products available that treat antibiotic-resistant infections.”

Under a 9-month, $12 million contract with Achaogen, Inc. of San Francisco, California, BARDA will support nonclinical studies, manufacturing, and preparatory activities for a Phase 3 clinical trial of C-scape to treat complicated urinary tract infections (cUTIs).

The contract can be extended for up to a total of three years and $18 million to support the Phase 3 trial, manufacturing, nonclinical studies, and the preparation of regulatory filings for U.S. Food and Drug Administration approval.

Because bacteria that cause cUTIs are becoming resistant to other oral antibiotics, medical practitioners increasingly rely on antibiotics administered intravenously or those of last resort to treat patients with these infections. By developing alternative antibiotics, such as C-scape, doctors could rely less often on last-resort antibiotics, giving bacteria less opportunity to develop resistance to these drugs and prolonging the drugs’ effectiveness.

Achaogen is also developing plazomicin for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. FDA has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections (BSI) caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections.

Tags: AntimicrobialsASPRAwardsBARDABioterrorismF. tularensisHHSPandemicY. pestis

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC